A first-of-its-kind clinical trial is offering renewed optimism to the millions of Americans living with age-related macular degeneration (AMD), a leading cause of vision loss for those over 60. Researchers are now assessing the safety and potential efficacy of using adult stem cells to treat the condition, representing a novel approach in a field with limited existing therapies. The phase 1/2a trial-conducted as of November 2025-marks a critical step toward determining if stem cell therapy can restore function to the damaged cells of the macula and improve vision for AMD sufferers [[1]].
1
Researchers are exploring the potential of adult stem cells to restore vision in individuals with age-related macular degeneration (AMD), a leading cause of permanent vision loss in Americans age 60 and older. The findings come from the first phase 1/2a clinical trial evaluating this approach in humans.
JetMedia Digital Agency
BN Babel
A new clinical trial offers hope for those suffering from age-related macular degeneration (AMD), a condition that affects the central part of the retina, known as the macula. The study, a phase 1/2a trial, investigated the use of adult stem cells to potentially recover vision lost to AMD.
In the United States, AMD is a major contributor to permanent vision impairment among adults aged 60 and over. This progressive disease damages the macula, impacting central vision crucial for tasks like reading and recognizing faces. The research represents a significant step toward potential new treatments for this debilitating condition, which currently has limited therapeutic options.
The phase 1/2a trial involved human participants and aimed to assess the safety and preliminary efficacy of using adult stem cells to address vision loss caused by AMD. Researchers evaluated whether the stem cells could help restore function to the damaged cells in the macula. Further research will be needed to confirm these initial findings and determine the long-term benefits of this approach.
